Chronic Hepatitis B
Conditions
Interventions
Treatment Group 1:'Cocktail therapy'
Treatment Group 2:Long-acting interferon + propofol tenofovir
Treatment Group 3:Propofol tenofovir
Sponsors
The Third People's Hospital of Shenzhen
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. All patients signed an informed consent form; 2. HBsAg(+), the course of disease is more than half a year; 3. HBeAg(+) or HBeAg(-); 4. Aged 18-65 years; 5. ALT >= the upper limit of normal, or liver biopsy with G2 or S2 and above lesions, or aged> 30 years, with normal ALT, family history of liver cirrhosis/liver cancer, and positive HBV DNA; 6. Female subjects of childbearing age have a negative pregnancy test before the test and can take effective contraceptive measures; those who agree to contraception within six months after the end of treatment during the treatment period (including female partners of female and male patients).
Exclusion criteria
Exclusion criteria: 1. Those with a known history of allergies to interferons, nucleoside antivirals, and colony stimulating factors; 2. Those who are combined with other viral infections such as HAV, HCV, HDV, HEV, and HIV; 3. There is evidence of decompensated liver disease (Child-Pugh score>7), history or evidence of liver disease caused by other reasons (such as autoimmune liver disease, alcoholic liver disease, non-alcoholic fatty liver disease, drug-induced hepatitis, hepatolenticular degeneration, etc.); 4. Pregnant or lactating women; 5. There was a history of alcohol or drug abuse within one year before the trial was enrolled in the screening; 6. When the treatment group involves interferon screening: neutrophil count = 7 points; 9. Chronic diseases that require long-term treatment, such as hypertension, diabetes, chronic obstructive pulmonary disease, etc.; 10. Malignant tumor; 11. Through imaging examination, it is clearly diagnosed as a patient with liver cancer, or a patient with symptoms and signs of hepatocellular carcinoma, AFP > 400ng/ml; 12. Previous history of antiviral therapy; 13. Other diseases that the researcher thinks are not suitable for inclusion in the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBsAg seroconversion rate; | — |
Countries
China
Contacts
Public ContactLi Guojun
The Third People's Hospital of Shenzhen
Outcome results
None listed